Lantheus (LNTH) Expected to Announce Earnings on Thursday

Lantheus (NASDAQ:LNTH) is projected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Lantheus to post earnings of $1.57 per share and revenue of $376.61 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Lantheus Trading Up 0.9 %

Shares of Lantheus stock opened at $78.95 on Tuesday. The business has a 50-day moving average price of $90.02 and a two-hundred day moving average price of $96.93. Lantheus has a 1-year low of $56.44 and a 1-year high of $126.89. The company has a market cap of $5.49 billion, a P/E ratio of 13.14 and a beta of 0.44.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on LNTH. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. Truist Financial restated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, JMP Securities restated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus price target of $131.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.